Joint Symposium 9
Neuroimaging Committee / European Academy of Neurology (EAN)
Accessible on-demand at any time

Session Title
The New ATN Diagnostic Concept in Alzheimer’s Disease

Chairperson
Henryk Barthel (Leipzig, Germany)

Programme
25 min Bruno Dubois (Paris, France / EAN): Introduction into the ATN Concept
20 min Victor Villemagne (Pittsburgh, United States of America): PET Tracers to Establish the ATN Profile
20 min Giovanni Frisoni (Geneva, Switzerland / EAN): A Critical Clinician’s Perspective on the ATN Concept
22 min Gaël Chételat (Caen, France): PET Data Supporting/Opposing the ATN Concept
3 min Session Summary by Chairperson

Educational Objectives
1. Understand the ATN concept and the rationale behind
2. Learn the ethical/clinical challenges related to this concept
3. Get an overview on the brain imaging data supporting/challenging this concept

Summary
Currently, Alzheimer’s disease (AD) is primarily defined/diagnosed as a syndromal construct. Despite intense research, no curative AD treatment is available. Mainly to stimulate the search for successful drugs, recently, an alternative concept was developed which defines AD primarily as a biological construct. This new A(myloid)T(tau)N(eurodegeneration) concept is a matter of intense debate. This symposium aims at providing an overview on this concept and the related pros & cons.

Key Words
Alzheimer’s disease, diagnosis, amyloid, tau, neurodegeneration